New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

MMP-7 Polyclonal Antibody, Cy5 Conjugated

Applications

  • WB
  • FCM
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Human
  • Mouse

Predicted Reactivity

  • Rat
Overview
Catalog # bs-0423R-Cy5
Product Name MMP-7 Polyclonal Antibody, Cy5 Conjugated
Applications WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Human, Mouse
Predicted Reactivity Rat
Specifications
Conjugation Cy5
Host Rabbit
Source KLH conjugated synthetic peptide derived from mouse MMP7
Immunogen Range 151-250/269
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Subcellular location Secreted, Extracellular matrix
Synonyms Matrilysin; Matrilysin uterine; Matrin; Matrix Metalloproteinase 7; MMP 7; MMP7; MPSL1; PUMP 1; Pump 1 protease; PUMP1; Uterine Matrilysin; Uterine metalloproteinase.
Background Matrix metalloproteinase-7 (MMP-7) also known as matrilysin and PUMP (EC 3.4.24.23) cleaves a number of substrates including collagen types IV and X, elastin, fibronectin, gelatin, laminin and proteoglycans. MMP-7 is closely related to the stromelysin family members but is encoded by a different gene. MMP-7 is the smallest of all the MMPs consisting of a pro-peptide domain and a catalytic domain. It lacks the hemopexin-like domain common to other members of the MMPs. MMP-7 is secreted as a 28kD proenzyme and can be activated in vitro by organomercurials and trypsin and in vivo by MMP-3 to a 18kD active MMP-7 enzyme. Once activated, MMP-7 can activate pro-MMP-1 and pro-MMP-9 but not pro-MMP-2. MMP-7 is widely expressed having been reported in elevated levels in cycling endometrium as well as in colorectal cancers and adenomas, hepatocellular carcinomas, rectal carcinomas, and approximately 50% of gliomas.
Application Dilution
WB 1:300-5000
FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200